Skip to main content
Andrei Shustov, MD, Oncology, Seattle, WA, UW Medicine/University of Washington Medical Center

AndreiRShustovMD

Oncology Seattle, WA

Assistant Professor, Medicine, University of Washington School of Medicine

Are you Dr. Shustov?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 55 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Andrei Shustov, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington and Pennsylvania. He is affiliated with UW Medicine/University of Washington Medical Center and Fred Hutchinson Cancer Center.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
  • Wellspan Health/York Hospital
    Wellspan Health/York HospitalResidency, Internal Medicine, 2000 - 2003
  • Crimea Med Univ
    Crimea Med UnivClass of 1993

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2003 - 2024
  • PA State Medical License
    PA State Medical License 2000 - 2003
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018

Press Mentions

  • Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award
    Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care AwardNovember 25th, 2019
  • Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN
    Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYNDecember 13th, 2017
  • Characterizing the Belinostat Response in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
    Characterizing the Belinostat Response in Patients with Relapsed or Refractory Angioimmunoblastic T-cell LymphomaNovember 9th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations